Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.27 a share - Earnings Preview

Tonix Pharmaceuticals Holding

06/08/2024 13:55

* Tonix Pharmaceuticals Holding Corp  TNXP.OQ   TNXP.O  is
expected to show a rise in quarterly revenue when it reports 
results on August 8 (estimated) for the period ending June
30 2024
    * The Chatham New Jersey-based  company is expected to
report
revenue of $3.5 million, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Tonix Pharmaceuticals
Holding
Corp is for a loss of $3.27 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tonix
Pharmaceuticals Holding Corp is $11.00​, above​ its last closing
price of $0.45. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -12.38      -12.48     -5.76     Beat    53.8
 Sep. 30 2024  -47.04      -52.59     -27.52    Beat    47.7
 Sep. 30 2023  -47.04      -47.68     -58.56    Missed  -22.8​
 Jun. 30 2023  -88.09      -88.16     -85.76    Beat    2.7
 ​​Mar.        -88.39      -97.00     -1.04     Missed  -7.2
 31 2023                              hundred           
 Dec. 31 2022  -1.08       -1.72      -1.12     Beat    34.9​
               hundred     hundred    hundred           
 Sep. 30 2022  -1.96       -2.04      -1.38     Beat    32.4
               hundred     hundred    hundred           
 Jun. 30 2022  -2.89       -2.89      -2.44     Beat    15.6
               hundred     hundred    hundred           
 This summary was machine generated August 6 at 12:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)